References
- Hacke W, Schwab S, Horn M, et al. ‘Malignant’ middle cerebral artery territory infarction: clinical course and prognostic signs. Arch Neurology 1996;53:309–15.
- Berrouschot J, Sterker M, Bettin S, et al. Mortality of space-occupying (‘malignant’) middle cerebral artery infarction under conservative intensive care. Intensive Care Med 1998;24:620–3.
- Heinsius T. Large infarcts in the middle cerebral artery territory. Etiology and outcome patterns. Neurology 1998;50:341–50.
- Ng LK. Massive cerebral infarction with severe brain swelling: a clinicopathological study. Stroke 1970;1:158–63.
- Huttner HB, Schwab S. Malignant middle cerebral artery infarction: clinical characteristics, treatment strategies, and future perspectives. Lancet Neurol 2009;8:949–58.
- Oppenheim C, Samson Y, Mana R, et al. Prediction of malignant middle cerebral artery infarction by diffusion-weighted imaging. Stroke 2000;31:2175–81.
- Schwab S. Early hemicraniectomy in patients with complete middle cerebral artery infarction. Stroke 1998;29:1888–93.
- Pullicino PM, Alexandrov AV, Shelton JA, et al. Mass effect and death from severe acute stroke. Neurology 1997;49:1090–5.
- Bamford J, Sandercock P, Dennis M, et al. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991;337:1521–26.
- Sparacia G, Iaia A, Assadi B, et al. Perfusion CT in acute stroke: predictive value of perfusion parameters in assessing tissue viability versus infarction. La Radiologia Medica 2007;112:113–22.
- Vahedi K, Hofmeijer J, Juettler E, et al. Early decompressive surgery in malignant infarction of the middle cerebral artery: a pooled analysis of three randomised controlled trials. Lancet Neurol. 2007;6:215–22.
- Fischer U, Arnold M, Nedeltchev K, et al. NIHSS score and arteriographic findings in acute ischemic stroke. Stroke 2005;36:2121–5.
- Thomalla GJ, Kucinski T, Schoder V, et al. Prediction of malignant middle cerebral artery infarction by early perfusion- and diffusion-weighted magnetic resonance imaging. Stroke 2003;34:1892–9.
- Souza LC, Yoo AJ, Chaudhry ZA, et al. Malignant CTA collateral profile is highly specific for large admission DWI infarct core and poor outcome in acute stroke. Am J Neuroradiol 2012;33:1331–1336.
- García-Berrocoso T, Giralt D, Llombart V, et al. Chemokines after human ischemic stroke: from neurovascular unit to blood using protein arrays. Translational Proteomics 2014;3:1–9.
- Tuttolomondo A, Di Raimondo D, di Sciacca R, et al. Inflammatory cytokines in acute ischemic stroke. Curr Pharmaceutical Des 2008;14:3574–89.
- Mildner A, Mack M, Schmidt H, et al. CCR2+Ly-6Chi monocytes are crucial for the effector phase of autoimmunity in the central nervous system. Brain 2009;132:2487–500.
- Cazareth J, Guyon A, Heurteaux C, et al. Molecular and cellular neuroinflammatory status of mouse brain after systemic lipopolysaccharide challenge: importance of CCR2/CCL2 signaling. J Neuroinflammation 2014;11:1742–2094.
- Zielasek J, Hartung H-P. Molecular mechanisms of microglial activation. Adv Neuroimmunology 1996;6:191–222.
- Turnbull AV, Rivier CL. Regulation of the hypothalamic-pituitary-adrenal axis by cytokines: actions and mechanisms of action. Physiol Rev 1999;79:1–71.
- Dantzer R. Cytokine-induced sickness behaviour: a neuroimmune response to activation of innate immunity. Eur J Pharmacol 2004;500:399–411.
- Biber K, Boddeke E. Neuronal CC chemokines: the distinct roles of CCL21 and CCL2 in neuropathic pain. Front Cell Neurosci 2014;8. doi:10.3389/fncel.2014.00210
- Kjeldsen L, Johnsen AH, Sengelov H, et al. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem. 1993;268:10425–32.
- Schmidt-Ott KM, Mori K, Kalandadze A, et al. Neutrophil gelatinase-associated lipocalin-mediated iron traffic in kidney epithelia. Curr Opin Nephrol Hypertens 2006;15:442–9.
- Flo TH, Smith KD, Sato S, et al. Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature 2004;432:917–21.
- Kobara H, Miyamoto T, Suzuki A, et al. Lipocalin2 enhances the matrix metalloproteinase-9 activity and invasion of extravillous trophoblasts under hypoxia. Placenta 2013;34:1036–43.
- Nakamura I, Hama S, Itakura S, et al. Lipocalin2 as a plasma marker for tumors with hypoxic regions. Sci Rep 2014;4. doi:10.1038/srep07235